Seek Returns logo

AMD vs. LLY: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at AMD and LLY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolAMDLLY
Company NameAdvanced Micro Devices, Inc.Eli Lilly and Company
CountryUnited StatesUnited States
GICS SectorInformation TechnologyHealth Care
GICS IndustrySemiconductors & Semiconductor EquipmentPharmaceuticals
Market Capitalization265.11 billion USD623.33 billion USD
ExchangeNasdaqGSNYSE
Listing DateMarch 17, 1980June 1, 1972
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of AMD and LLY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

AMD vs. LLY: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolAMDLLY
5-Day Price Return-1.92%-1.12%
13-Week Price Return47.56%-2.78%
26-Week Price Return42.44%-19.81%
52-Week Price Return7.69%-27.13%
Month-to-Date Return-7.35%-6.05%
Year-to-Date Return35.24%-9.93%
10-Day Avg. Volume55.71M5.47M
3-Month Avg. Volume51.84M4.51M
3-Month Volatility45.58%40.35%
Beta1.940.45

Profitability

Return on Equity (TTM)

AMD

4.88%

Semiconductors & Semiconductor Equipment Industry

Max
52.74%
Q3
23.49%
Median
11.60%
Q1
3.23%
Min
-20.69%

AMD’s Return on Equity of 4.88% is on par with the norm for the Semiconductors & Semiconductor Equipment industry, indicating its profitability relative to shareholder equity is typical for the sector.

LLY

88.36%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

AMD vs. LLY: A comparison of their Return on Equity (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

AMD

9.57%

Semiconductors & Semiconductor Equipment Industry

Max
44.17%
Q3
22.38%
Median
11.95%
Q1
3.21%
Min
-25.16%

AMD’s Net Profit Margin of 9.57% is aligned with the median group of its peers in the Semiconductors & Semiconductor Equipment industry. This indicates its ability to convert revenue into profit is typical for the sector.

LLY

25.91%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

AMD vs. LLY: A comparison of their Net Profit Margin (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

AMD

7.66%

Semiconductors & Semiconductor Equipment Industry

Max
58.03%
Q3
27.84%
Median
12.45%
Q1
5.15%
Min
-28.61%

AMD’s Operating Profit Margin of 7.66% is around the midpoint for the Semiconductors & Semiconductor Equipment industry, indicating that its efficiency in managing core business operations is typical for the sector.

LLY

32.37%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

AMD vs. LLY: A comparison of their Operating Profit Margin (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Profitability at a Glance

SymbolAMDLLY
Return on Equity (TTM)4.88%88.36%
Return on Assets (TTM)3.97%16.02%
Net Profit Margin (TTM)9.57%25.91%
Operating Profit Margin (TTM)7.66%32.37%
Gross Profit Margin (TTM)47.62%82.64%

Financial Strength

Current Ratio (MRQ)

AMD

2.49

Semiconductors & Semiconductor Equipment Industry

Max
8.42
Q3
4.70
Median
2.75
Q1
2.07
Min
1.04

AMD’s Current Ratio of 2.49 aligns with the median group of the Semiconductors & Semiconductor Equipment industry, indicating that its short-term liquidity is in line with its sector peers.

LLY

1.28

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

AMD vs. LLY: A comparison of their Current Ratio (MRQ) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

AMD

0.05

Semiconductors & Semiconductor Equipment Industry

Max
1.09
Q3
0.45
Median
0.22
Q1
0.01
Min
0.00

AMD’s Debt-to-Equity Ratio of 0.05 is typical for the Semiconductors & Semiconductor Equipment industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

LLY

2.18

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

AMD vs. LLY: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

AMD

14.93

Semiconductors & Semiconductor Equipment Industry

Max
174.00
Q3
81.10
Median
27.22
Q1
7.28
Min
-4.26

AMD’s Interest Coverage Ratio of 14.93 is positioned comfortably within the norm for the Semiconductors & Semiconductor Equipment industry, indicating a standard and healthy capacity to cover its interest payments.

LLY

20.36

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

AMD vs. LLY: A comparison of their Interest Coverage Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

SymbolAMDLLY
Current Ratio (MRQ)2.491.28
Quick Ratio (MRQ)1.560.53
Debt-to-Equity Ratio (MRQ)0.052.18
Interest Coverage Ratio (TTM)14.9320.36

Growth

Revenue Growth

AMD vs. LLY: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

AMD vs. LLY: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

AMD

0.00%

Semiconductors & Semiconductor Equipment Industry

Max
4.16%
Q3
1.78%
Median
0.74%
Q1
0.00%
Min
0.00%

AMD currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

LLY

0.77%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

LLY’s Dividend Yield of 0.77% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

AMD vs. LLY: A comparison of their Dividend Yield (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

AMD

0.00%

Semiconductors & Semiconductor Equipment Industry

Max
196.12%
Q3
87.72%
Median
26.57%
Q1
0.00%
Min
0.00%

AMD has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

LLY

36.46%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

AMD vs. LLY: A comparison of their Dividend Payout Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Dividend at a Glance

SymbolAMDLLY
Dividend Yield (TTM)0.00%0.77%
Dividend Payout Ratio (TTM)0.00%36.46%

Valuation

Price-to-Earnings Ratio (TTM)

AMD

93.96

Semiconductors & Semiconductor Equipment Industry

Max
109.37
Q3
57.11
Median
28.95
Q1
22.13
Min
11.14

A P/E Ratio of 93.96 places AMD in the upper quartile for the Semiconductors & Semiconductor Equipment industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.

LLY

47.48

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

At 47.48, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

AMD vs. LLY: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

AMD

9.00

Semiconductors & Semiconductor Equipment Industry

Max
16.09
Q3
10.10
Median
4.82
Q1
2.60
Min
0.93

AMD’s P/S Ratio of 9.00 aligns with the market consensus for the Semiconductors & Semiconductor Equipment industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

LLY

12.30

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

With a P/S Ratio of 12.30, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.

AMD vs. LLY: A comparison of their Price-to-Sales Ratio (TTM) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

AMD

3.86

Semiconductors & Semiconductor Equipment Industry

Max
13.56
Q3
6.75
Median
3.68
Q1
1.89
Min
0.60

AMD’s P/B Ratio of 3.86 is within the conventional range for the Semiconductors & Semiconductor Equipment industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

LLY

40.43

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

AMD vs. LLY: A comparison of their Price-to-Book Ratio (MRQ) against their respective Semiconductors & Semiconductor Equipment and Pharmaceuticals industry benchmarks.

Valuation at a Glance

SymbolAMDLLY
Price-to-Earnings Ratio (TTM)93.9647.48
Price-to-Sales Ratio (TTM)9.0012.30
Price-to-Book Ratio (MRQ)3.8640.43
Price-to-Free Cash Flow Ratio (TTM)65.86326.03